葡萄糖类1受体激动剂和肺高血压的风险
medRxiv : the preprint server for health sciences
|September 26, 2025
概括
类似葡萄糖类1受体激动剂 (GLP-1 RAs) 可能降低糖尿病患者患肺高血压 (PH) 的风险. 这项研究发现,与DPP-4抑制剂相比,GLP-1RA使用与PH风险降低28%.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 肺部病理学 肺部病理学
背景情况:
- 心脏代谢性疾病是肺高血压 (PH) 的首要驱动因素,这种疾病与死亡率增加和心力衰竭住院病例有关.
- 对于PH的预防策略是有限的,突出显示了对新型治疗方法的需求.
- 葡萄糖类1受体激动剂 (GLP-1 RAs) 显示出显著的心脏代谢益处,将它们定位为预防PH的潜在干预措施.
研究的目的:
- 为了研究葡萄糖类1受体激动剂 (GLP-1 RA) 暴露与患肺高血压 (PH) 的风险之间的关联.
- 评估GLP-1RA作为糖尿病患者PH的预防疗法的潜力.
主要方法:
- 一个回顾性队列研究,利用退伍军人卫生管理局的数据.
- 纳入标准:糖尿病患者和没有PH的回声心电图,启动GLP-1RA或Dipeptidyl Peptidase 4抑制剂 (DPP-4i).
- 使用反向概率加权 (IPW) 来调整混因素,将GLP-1RA的新用户与DPP-4is的新用户进行比较.
主要成果:
- 该研究包括4109名GLP-1RA用户和7384名DPP-4i用户;GLP-1RA用户略小.
- 反向概率加权实现了两组之间的共变量平衡.
- 与DPP-4i暴露相比,GLP-1 RA暴露与发展PH的风险降低了28% (HR,0.72;95% CI 0.61-0.84).
结论:
- 类似葡萄糖1受体激动剂 (GLP-1 RA) 的使用与肺高血压 (PH) 发病风险降低有关.
- 这些发现需要通过临床试验和机理学研究进行进一步的研究.
- 作为PH的预防疗法,GLP-1RA可能具有潜力,特别是在高危人群中.
相关概念视频
Glucagon-like Receptor Agonists
848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
462
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
462
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594


